Cargando…
Sharing data from MS clinical trials: Opportunities, challenges, and future directions
The treatment of people affected by multiple sclerosis, particularly the relapsing forms of the disease, has been transformed by the availability of various therapeutic agents. This landmark progress is due to an enormous foundation of clinical research and, particularly, numerous phase II and III c...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4594087/ https://www.ncbi.nlm.nih.gov/pubmed/26438302 http://dx.doi.org/10.1177/1352458515608005 |
_version_ | 1782393406145691648 |
---|---|
author | Coetzee, Timothy |
author_facet | Coetzee, Timothy |
author_sort | Coetzee, Timothy |
collection | PubMed |
description | The treatment of people affected by multiple sclerosis, particularly the relapsing forms of the disease, has been transformed by the availability of various therapeutic agents. This landmark progress is due to an enormous foundation of clinical research and, particularly, numerous phase II and III clinical trials. Although the research community has many reasons to take pride in this progress, a fundamental question remains about whether opportunities for additional research are being lost due to inadequate clinical trial data sharing. |
format | Online Article Text |
id | pubmed-4594087 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-45940872015-10-20 Sharing data from MS clinical trials: Opportunities, challenges, and future directions Coetzee, Timothy Mult Scler Personal Viewpoint The treatment of people affected by multiple sclerosis, particularly the relapsing forms of the disease, has been transformed by the availability of various therapeutic agents. This landmark progress is due to an enormous foundation of clinical research and, particularly, numerous phase II and III clinical trials. Although the research community has many reasons to take pride in this progress, a fundamental question remains about whether opportunities for additional research are being lost due to inadequate clinical trial data sharing. SAGE Publications 2015-10 /pmc/articles/PMC4594087/ /pubmed/26438302 http://dx.doi.org/10.1177/1352458515608005 Text en © The Author(s), 2015 http://creativecommons.org/licenses/by-nc/3.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 3.0 License (http://www.creativecommons.org/licenses/by-nc/3.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Personal Viewpoint Coetzee, Timothy Sharing data from MS clinical trials: Opportunities, challenges, and future directions |
title | Sharing data from MS clinical trials: Opportunities, challenges, and future directions |
title_full | Sharing data from MS clinical trials: Opportunities, challenges, and future directions |
title_fullStr | Sharing data from MS clinical trials: Opportunities, challenges, and future directions |
title_full_unstemmed | Sharing data from MS clinical trials: Opportunities, challenges, and future directions |
title_short | Sharing data from MS clinical trials: Opportunities, challenges, and future directions |
title_sort | sharing data from ms clinical trials: opportunities, challenges, and future directions |
topic | Personal Viewpoint |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4594087/ https://www.ncbi.nlm.nih.gov/pubmed/26438302 http://dx.doi.org/10.1177/1352458515608005 |
work_keys_str_mv | AT coetzeetimothy sharingdatafrommsclinicaltrialsopportunitieschallengesandfuturedirections |